Vnitr Lek 2013, 59(7):606-611

Hepatic involvement in patients with non-Hodgkin's lymphoma

M. Trněný^1,*, J. Šálková¹, J. Dlouhá¹, J. Stříteský²

¹ I. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Marek Trněný, CSc.

² Ústav patologie 1. lékařské fakulty UK a VFN Praha, přednosta doc. MUDr. Pavel Dundr, Ph.D.

Non-Hodgkin's lymphoma (NHL) represent the most frequent hematological malignancy with frequent extranodal involvement. We have identified 79 pts (4.6%) out of 1,712 patients with NHL, who were diagnosed in our center between 1999-2010. Five cases were primary extranodal lymphomas and we have observed one primary hepatic lymphoma (0.015%). The most frequent (61.3%) NHL subtype in our cohort was diffuse large B-cell lymphoma. B-NHL formed 92.4% of all lymphomas. We have observed high number of HBsAg positive patients (10%). The whole group have poor prognostic features with high number of patients (85%) with intermediate-high and high risk according to international prognostic index. The patients were treated with chemotherapy in 95%, B-NHL patients recieved immunochemotherapy with rituximab in 77%. The median progression free survival, resp. overall survival 4.6, resp. 8.4 years in the whole group and 1.4, resp. 8.4 years in diffuse large B-cell lymphoma were observed with median follow-up 4.5 years. The outcome of T-NHL patients was significantly worse with overall survival median 1.2 vs 8.4 years (p < 0.033). The patients with B-NHL treated by immunochemoterapy with rituximab had significant death risk reduction (HR 0.44, p = 0.03) compared to the patients treated with chemotherapy.

Keywords: lymphoma; non-Hodgkin's lymphoma; hepatic impairment; extranodal impairment; immunochemotherapy; rituximab

Received: May 16, 2013; Published: July 1, 2013  Show citation